- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1880-8190
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Complement-targeted therapy: development of C5- and C5a-targeted inhibition ; volume:36 ; number:1 ; day:3 ; month:6 ; year:2016 ; pages:1-5 ; date:12.2016
Inflammation and regeneration ; 36, Heft 1 (3.6.2016), 1-5, 12.2016
- Creator
-
Horiuchi, Takahiko
- Contributor
-
Tsukamoto, Hiroshi
SpringerLink (Online service)
- DOI
-
10.1186/s41232-016-0013-6
- URN
-
urn:nbn:de:1111-201606123496
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:59 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Horiuchi, Takahiko
- Tsukamoto, Hiroshi
- SpringerLink (Online service)
Other Objects (12)
Complement-targeted therapy for autoimmune diseases
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors
Complement‐targeted therapeutics: Are we there yet, or just getting started?
Complement C5 Contributes to Brain Injury After Subarachnoid Hemorrhage
The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies
Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis
Complement C5a blockade is sufficient to resolve crystalline thrombotic microangiopathy
Complement C5a-induzierte Funktionsänderung neutrophiler Granulozyten während der systemischen Entzündung
Complement C5a potentiates uric acid crystal‐induced IL‐1β production
Targeted inhibition of the human papillomavirus 16 E6 oncoprotein
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
Molecular modulators of cardiac stress targeted by PDE5 inhibition
Complement-targeted therapy for autoimmune diseases
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors
Complement‐targeted therapeutics: Are we there yet, or just getting started?
Complement C5 Contributes to Brain Injury After Subarachnoid Hemorrhage
The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies
Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis
Complement C5a blockade is sufficient to resolve crystalline thrombotic microangiopathy
Complement C5a-induzierte Funktionsänderung neutrophiler Granulozyten während der systemischen Entzündung
Complement C5a potentiates uric acid crystal‐induced IL‐1β production
Targeted inhibition of the human papillomavirus 16 E6 oncoprotein
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
Molecular modulators of cardiac stress targeted by PDE5 inhibition
Complement-targeted therapy for autoimmune diseases
Valproic acid attenuates cellular senescence in diabetic kidney disease through the inhibition of complement C5a receptors
Complement‐targeted therapeutics: Are we there yet, or just getting started?
Complement C5 Contributes to Brain Injury After Subarachnoid Hemorrhage
The Role of the Complement System in Chronic Inflammatory Demyelinating Polyneuropathy: Implications for Complement-Targeted Therapies
Inhibition of complement C5a prevents breakdown of the blood-brain barrier and pituitary dysfunction in experimental sepsis
Complement C5a blockade is sufficient to resolve crystalline thrombotic microangiopathy
Complement C5a-induzierte Funktionsänderung neutrophiler Granulozyten während der systemischen Entzündung
Complement C5a potentiates uric acid crystal‐induced IL‐1β production
Targeted inhibition of the human papillomavirus 16 E6 oncoprotein
PP2A inhibition overcomes acquired resistance to HER2 targeted therapy